Individualized Treatment Selection and Sequencing Enhances Bladder and Prostate Cancer Management
Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.
Source: onclive.com